Skip to main content
Fig. 5 | Genome Medicine

Fig. 5

From: Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial

Fig. 5

Immunological changes of immune cells in response to pembrolizumab. A tSNE analysis of immune cells colored by inferred cell type and separated by pembrolizumab treatment time point. Pre-treatment (left panel) and post-treatment (right panel). B Bar graph representation of immune cell composition based on pembrolizumab treatment time point. The p-value has been calculated using the chi-squared test. C Bar graph representation of immune cell composition based on pembrolizumab treatment time point and response. The p-values have been calculated using chi-squared tests. D Violin plot representation of cytotoxic T cells between pre- and post-pembrolizumab treatment in patients who achieve PR or SD (left panel) and patients with PD (right panel). The p values are calculated by a two-sided Wilcoxon rank-sum test. E Volcano plot representation of differentially expressed gene analysis in cytotoxic T cells between patients who achieve PR or SD and patients with PD. Genes with > 0.5 or < − 0.5 log2 fold change and < 0.05 p-value are colored in red and blue, respectively. F Gene Ontology (GO) analysis of differentially expressed genes in E. tSNE, t-stochastic neighbor embedding; PR, partial response; SD, stable disease; PD, progressive disease

Back to article page